Credit: Boehringer Ingeheim. The high-concentration formultion (100mg/mL) is available as a prefilled syringe (40mg/0.4mL) or prefilled autoinjector. Cyltezo is an interchangeable biosimilar and can ...

Boehringer Ingelheim has received the Food and Drug Administration’s blessing for the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company’s interchangeable ...

Please provide your email address to receive an email when new articles are posted on . As with the low-concentration (50 mg/mL) version of Cyltezo (adalimumab-adbm ...

(RTTNews) - Sandoz (SDZNY) has unveiled Hyrimoz or adalimumab citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively ...

The US Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of adalimumab-adbm (Cyltezo), a biosimilar of Humira, Boehringer Ingelheim announced. This ...

The FDA approved the first high-concentration adalimumab biosimilar. A low-concentration version of the biosimilar, Hadlima, was already approved. Both versions will launch in July 2023. Last week, ...

Credit: Getty Images. The approval of the new citrate-free, high-concentration formulation was based on data from a phase 1 pharmacokinetics bridging study. The Food and Drug Administration (FDA) has ...

(RTTNews) - ASLAN Pharmaceuticals (ASLN) and Thermo Fisher Scientific Inc (TMO) announced a partnership to manufacture a high concentration formulation of eblasakimab for Phase 3 clinical trials.

REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients ...

S-HiCon TM is designed to maximize drug delivery and stability through high-concentration formulation The platform can address challenges associated with viscosity and achieve stable liquid ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, ...